• 1
    International Agency for Research on Cancer, World Health Organization. Infection with Helicobacter pylori. In: Schistosomes, Liver Flukes and Helicobacter pylori. Lyon: IARC, 1994: 177202.
  • 2
    Malfertheiner P, Mégraud F, Morain CO, et al. Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 3
    Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 23308.
    Direct Link:
  • 4
    Janssen MJR, Van Oijen AHAM, Verbeek ALM, Jansen JBMJ, De Boer WA. A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Aliment Pharmacol Ther 2001; 15: 61324.
  • 5
    Perri F, Villani MR, Festa V, Quitadamo M, Andriulli A. Predictors of failure of Helicobacter pylori eradication with the standard ‘Maastricht triple therapy’. Aliment Pharmacol Ther 2001; 15: 10239.
  • 6
    Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12: 3838.
  • 7
    Deltenre M, Jonas C, Van Gossum M, Buser M, Otero J, De Koster E. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. Eur J Gastroenterol Hepatol 1997; 7(Suppl. 1): S3944.
  • 8
    Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 4837.
  • 9
    Wong BCY, Chang FY, Abid S, et al. Triple therapy with clarithromycin, omeprazole, and amoxycillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14: 152935.
  • 10
    Lee JM, Breseling NP, Hyde DK, Buckley MJ, O'Morain CA. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13: 48996.
  • 11
    Eclissato C, Marchioretto MA, Mendonca S, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002; 7: 539.
  • 12
    Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 6038.
  • 13
    Vakil N, McSorley D, Hahn B, Ciociola A, Webb D. Clarithromycin resistant Helicobacter pylori in the United States. Am J Gastroenterol 1998; 93: 14325.
    Direct Link:
  • 14
    Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 24853.
  • 15
    Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 7158.
  • 16
    De Francesco V, Zullo A, Hassan C, et al. Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Digest Liver Dis 2001; 33: 6769.
  • 17
    Altman DG, Schulz KF, Moher D, et al. The Revised CONSORT Group Statement for Reporting Randomized Trials. Explanation and Elaboration. Ann Intern Med 2001; 134: 66394.
  • 18
    Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GNJ. Functional gastroduodenal disorders. Gut 1999; 45(Suppl. 2): S113742.
  • 19
    Working Party of the European Helicobacter pylori Study Group. Technical annex: tests used to assess Helicobacter pylori infection. In: Guidelines for clinical trials in Helicobacter pylori infection. Gut 1997; 41(Suppl. 2): S108.
  • 20
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the updated Sydney System. Am J Surg Pathol 1996; 20: 116181.
  • 21
    Newcombe RG, Altman DG. Proportions and their differences. In: AltmanDG, MachinD, TrevorNB, GardnerMJ, eds. Statistics with Confidences, 2nd edn. London: BMJ Books, 2000.
  • 22
    Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 1638.
  • 23
    Sonnenberg A, Schwartz SJ, Cutler A, Vakil N, Bloom BS. Cost savings in duodenal ulcer treatment through H. pylori eradication compared to conventional therapies: results of a randomized, double-blind, multicenter trial. Arch Intern Med 1998; 158: 85260.
  • 24
    Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996; 31(Suppl. 215): 7481.
  • 25
    Moshkowitz M, Konikoff FM, Peled Y, et al. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995; 36: 8457.
  • 26
    Perri F, Clemente R, Festa V, et al. Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori. Ital J Gastroenterol Hepatol 1998; 30: 14650.
  • 27
    Murakami K, Fujioka T, Okimoto T, Sato R, Kodama M, Nasu M. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy. Int J Antimicrob Agents 2002; 19: 6770.
  • 28
    DeBoer WA, Driessen MMW, Jansz AR, Tytgat NJ. Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study. Eur J Gastroenterol Hepatol 1995; 7: 118994.
  • 29
    Kung NNS, Sung JJY, Yuen NWF, et al. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy. Am J Gastroenterol 1997; 92: 43841.
  • 30
    Phull PS, Griffiths AE, Halliday D, Jacyna MR. One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. J Antimicrob Chemother 1995; 36: 10858.
  • 31
    Lahaie R, Farley A, Dallaire C, et al. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori. Can J Gastroenterol 2001; 15: 5815.
  • 32
    Borody TJ, Andrews P, Fracchia G, Brandl S, Shortis NP, Bae H. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 47781.
  • 33
    Sotudehmanesh R, Malekzadeh R, Fazel A, et al. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. J Gastroenterol Hepatol 2001; 16: 2648.
  • 34
    Calvet X, Ducons J, Guardiola J, et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection — a randomized trial. Aliment Pharmacol Ther 2002; 4: 12617.
  • 35
    De Boer WA. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. J Clin Gastroenterol 1996; 22: 3136.
  • 36
    Phillips RH, Whitehead MW, Doig LA, et al. Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe? Helicobacter 2001; 6: 1516.
  • 37
    Bazzoli F, Bianchi Porro G, Maconi G, Molteni M, Pozzato P, Zagari RM. Treatment of Helicobacter pylori infection. Indications and regimens: an update. Digest Liver Dis 2002; 34: 7083.
  • 38
    Savarino V, Zentilin P, Pivari M, et al. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 4: 893900.
  • 39
    Romano M, Iovene MR, Montella F, Vitale LM, De Simone T, Del Vecchio Blanco C. Pretreatment antimicrobial-susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000; 95: 33178.
    Direct Link:
  • 40
    Toracchio S, Cellini L, Di Campli E, et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 163943.
  • 41
    Tucci A, Varoli O, Corinaldesi R, et al. Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients. Ital J Gastroenterol 1993; 25: 657.
  • 42
    Bazzoli F, Zagari M, Pozzato P, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998; 12: 43945.
  • 43
    Zullo A, Hassan C, Campo C, et al. A triple therapy regimen after failed Helicobacter pylori treatments. Aliment Pharmacol Ther 2001; 15: 11937.
  • 44
    Perri F, Festa V, Clemente R, Quitadamo M, Andriulli A. Rifabutin-based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens. Aliment Pharmacol Ther 2000; 14: 3116.
  • 45
    Zullo A, Hassan C, Lorenzetti R, Morini S. Helicobacter pylori eradication: do we have another ace up our sleeve? Digest Liver Dis 2001; 33: 8056.
  • 46
    Zullo A, Hassan C, Marignani M, Angeletti S, Morini S. A 10-day ‘rescue’ therapy for Helicobacter pylori eradication failure patients: preliminary data. Digest Liver Dis 2002; 34(Suppl. 1): A19(Abstract).